Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…Abstract Number: 0671 • ACR Convergence 2020
Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up
Background/Purpose: Gout is an independent cardiovascular (CV) risk factor. This excess of morbidity and mortality requires optimal management, especially in high-risk individuals. Therefore, the inclusion…Abstract Number: 0672 • ACR Convergence 2020
Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares
Background/Purpose: Cross-sectional radiologic evidence suggests monosodium urate crystal deposition among gout patients is a symmetrical phenomenon,1 but no study has examined the longitudinal patterns in…Abstract Number: 0673 • ACR Convergence 2020
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Background/Purpose: Gout can cause uric acid deposition in joints, soft tissues, and organs (1) and is associated with heart disease, kidney disease, hypertension, hyperlipidemia, diabetes,…Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…Abstract Number: 0677 • ACR Convergence 2020
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
Background/Purpose: Consistent, though limited, published data suggests that methotrexate (MTX) improves treatment response in patients treated with pegloticase for uncontrolled (refractory) gout. Recent case series1-3…Abstract Number: 0678 • ACR Convergence 2020
Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout
Background/Purpose: Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition in the joints. Despite this well-understood pathophysiologic mechanism of disease and ACR and EULAR…Abstract Number: 0680 • ACR Convergence 2020
Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Levels in Gout Patients
Background/Purpose: Though hyperuricemia is implicated in cardiovascular disease, the metabolic syndrome, and type 2 diabetes in both gout and in asymptomatic patients, the core metabolism…Abstract Number: 0681 • ACR Convergence 2020
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Background/Purpose: Spinal gout is reported as a rare event, presenting as acute back pain, neuropathy, and spinal compression. Diagnosis is commonly based on identification of…Abstract Number: 0682 • ACR Convergence 2020
Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout
Background/Purpose: To understand the role of inflammatory cytokines and oxidative stress biomarkers in the renal disease in people with gout. We hypothesized that higher gout…Abstract Number: 0683 • ACR Convergence 2020
Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate
Background/Purpose: In an open-label trial in adult patients with uncontrolled gout (MIRROR open-label [OL] trial) evaluating pegloticase co-treatment with methotrexate (MTX), 78.6% patients maintained serum…Abstract Number: 0684 • ACR Convergence 2020
The Shrinking Toe: A Sign of Crystal Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy
Background/Purpose: Serum urate (SU) lowering has been reported to improve gout erosions. We observed that it may also lead to compaction of toe MTP or…Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…Abstract Number: 0688 • ACR Convergence 2020
The Discontinuation of Allopurinol in the Inpatient Setting and the Risk of Gout Flare: A Community-Hospital Experience
Background/Purpose: The discontinuation of urate-lowering therapy (ULT) in the outpatient setting increases the risk of gout flare. It was reported that in hospitalized patients with…Abstract Number: 0689 • ACR Convergence 2020
The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study
Background/Purpose: Knowledge gaps exist regarding time-trends for the main causes (Cardiac/renal disease vs. infections) hospitalizations in gout. Therefore, we examined whether specific causes (cardiovascular, renal,…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »